Antithrombotic Mechanisms of Urokinase lmmobilized Polyurethane

Summary

Urokinase immobilized polymer is highly antithrombotic, which cannot be explained only by fibrinolysis. We immobllized 10 IU/cm² of urokinase to polyurethane by using maleic anhydride methylvinyl ether copolymer as a carrier. Then we incubated blood in circular tubes made of this material, measured the clotting factors and observed the surface of the tubes after incubation by scanning electronmicroscopy and immunofluorescence microscopy. After 5 min incubation, the relative activities of factors V, VIII, IX, X and XII, fibrinogeil, plasminogen and α₂ plasmin inhibitor decreased, but the activity of factor VII increased. No platelet adhesion to the surface of the urokinase immobilized polyurethane was observed and there was no significant adsorption of serum proteins, including fibrinogen, fibronectin and vWF antigen, or the surface. Urokinase-immobilized polyurethane catalyzed the digestion of clotting factors as well as fibrinolysis and also inhibited platelet adhesion on its surface probably by inhibiting protein adsorption and its clinical application including vessel prosthesis should be developed further.

• References

• 1 Kusserow BK, Larrow R. Use of surface bonded, covalently crosslinked urokinase as an approach to the creation of a throm-boresistant synthetic surface with fibrinolytic capability. Circulation Suppl 1972; 2: 54
• 2 Sugitachi A, Kawahara T, Kodama J, Kikkawa Y, Takagi K. Antithrombogenicity of immobilized urokinase and its clinical significance. Blut 1978; 37: 31-36
• 3 Kitamoto Y, Fukui H, Iwabuchi K, Taguma Y, Monma H, Ishizaki M, Takahashi H, Nakayama M, Sekino H. A femoral vein catheter with immobilized urokinase (UKFC) as an antithrombotic blood access. Trans Am Soc Artif Intern Organs 1987; 10: 136-139
• 4 Clark DT, Peeling J. Application of ESCA to polymer chemistry. VIII. Surface Structures of AB block copolymers of polydimethyl-siloxane and polystyrene. J Polym Sci Polym Chem Ed 1976; 14: 533-542
• 5 Morita T, Kato H, Iwanaga S, Takada K, Kimura T, Sakakibara S. New fluorogenic substrates for α-thrombin, factor Xa, kallikreins, and urokinase. J Biochem 1977; 82: 1495-1498
• 6 Chandler AB. In vitro thrombotic coagulation of the blood. Lab Invest 1958; 7: 110-114
• 7 Yabushita Y. Studies on the properties of immobilized urokinase: effects of pH and temperature. Biotechnol Appl Biochem 1988; 10: 294-300
• 8 Yabushita Y, Suyama K, Takagi K. Studies on properties of immobilized urokinase. Chem Pharm Bull 1988; 36: 954-958
• 9 Kitamoto Y, Fukui H, Deguchi T, Matsushita K, Kuwahara K, Nakayama M, Sato T. Changes of clotting and fibrinolytic proteins in serum during hemodialysis with urokinase immobilized femoral vein catheter. J Jpn Soc Dial Ther 1989; 22: 965-969
• 10 Henriksson P, Nilsson IM. Effects of leucocytes, plasmin and thrombin on clotting factors - a comparative in vitro study. Thromb Res 1979; 16: 301-312
• 11 Radcliffe R, Nemerson Y. Activation and control of Factor VII by activated Factor X and thrombin. J Biol Chem 1975; 250: 388-395
• 12 Schafer AI, Adelman BA. Plasmin inhibition of platelet function and of arachidonate metabolism. J Clin Invest 1985; 75: 456-461
• 13 Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79: 1749-1754
• 14 Adelman B, Michelson AD, Greenberg J, Handin RI. Proteolysis of platelet glycoprotein lb by plasmin is facilitated by plasmin lysine-binding regions. Blood 1986; 68: 1280-1284
• 15 Laura R, Robinson DJ, Bing DH. (p-Amidinophenyl)methanesul-fonyl fluoride, an irreversible inhibitor of serine proteases. Biochemistry 1980; 19: 4859-4864